Turning Point Therapeutics Inc (TPTX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Athena M. Countouriotis
Employees:
250
10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO, CA 92121
858-926-5251

Turning Point Therapeutics, Inc. engages in designing and developing therapies that target genetic drivers of cancer. Its lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC)

Data derived from most recent annual or quarterly report
Market Cap 3.772 Billion Shares Outstanding49.62 Million Avg 30-day Volume 962.413 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.87
Price to Revenue3710.4566 Debt to Equity0.0 EBITDA-335.554 Million
Price to Book Value4.7163 Operating Margin-34185.813500000004 Enterprise Value2.922 Billion
Current Ratio16.828 EPS Growth-1.153 Quick Ratio16.557
1 Yr BETA 1.0812 52-week High/Low 82.2 / 23.77 Profit Margin-33959.0278
Operating Cash Flow Growth-189.2363 Altman Z-Score43.1826 Free Cash Flow to Firm -226.25 Million
View SEC Filings from TPTX instead.

View recent insider trading info

Funds Holding TPTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TPTX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-08-17:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-24:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2022-06-21:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-06-03:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-03:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-05:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2022-04-13:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-04:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • Prospectus

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MACHADO PATRICK

    • Director
    0 2022-08-17 1

    GALLAGHER CAROL GILTNER

    • Director
    0 2022-08-17 1

    ALLES MARK J

    • Director
    0 2022-08-17 1

    COUNTOURIOTIS ATHENA PRESIDENT & CEO

    • Officer
    • Director
    0 2022-08-17 2

    GEORGE SIMEON

    • Director
    0 2022-08-17 1

    NICHOLSON GARRY A

    • Director
    0 2022-08-17 1

    HIRMAND MOHAMMAD EVP AND CHIEF MEDICAL OFFICER

    • Officer
    0 2022-08-17 2

    TOMBESI PAOLO EVP & CHIEF FINANCIAL OFFICER

    • Officer
    0 2022-08-17 3

    BODEM BARBARA W.

    • Director
    0 2022-08-17 1

    SUN BRIAN SVP & GENERAL COUNSEL

    • Officer
    0 2022-08-17 3

    SABUS STEVE M SVP & CHIEF COMMERCIAL OFFICER

    • Officer
    0 2022-08-17 3

    NORTH ANNETTE EVP & GENERAL COUNSEL

    • Officer
    86,579 2022-02-09 1

    REICH SIEGFRIED EVP & CHIEF SCIENTIFIC OFFICER

    • Officer
    65,848 2022-02-09 1

    PARTRIDGE ANDREW JOHN EVP & CHIEF COMMERCIAL OFFICER

    • Officer
    96,961 2022-02-09 1

    VAN HOOSE KYRI K. PRINCIPAL ACCOUNTING OFFICER

    • Officer
    0 2021-05-14 0

    BAKER BRIAN LEE SVP OF FINANCE AND ADMIN.

    • Officer
    32,443 2021-03-22 0

    LARSON YI EVP & CHIEF FINANCIAL OFFICER

    • Officer
    7,321 2021-02-08 0

    GORDON CARL L

    • Director
    0 2020-06-15 0

    GUJRATHI SHEILA

    • Director
    0 2020-06-15 0

    CHACKO JACOB

    • Director
    0 2020-06-15 0

    CUI JINGRONG JEAN

    • Director
    1,841,681 2020-06-09 0

    GLAXOSMITHKLINE PLC

    • Director
    2,253,660 2020-05-21 0

    CORMORANT ASSET MANAGEMENT, LP

    CHEN BIHUA

    • Director
    • 10% Owner
    • FORMER 10% OWNER
    No longer subject to file 2019-08-12 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VI LLC

    • Director
    2,027,550 2019-04-22 0

    LU HONGBO

    • Director
    1,742,550 2019-04-22 0

    ALTA PARTNERS

    ALTA CALIFORNIA PARTNERS II LP

    ALTA CALIFORNIA MANAGEMENT PARTNERS II LLC

    ALTA EMBARCADERO PARTNERS II LLC

    ALTA CALIFORNIA PARTNERS II, L.P. -- NEW POOL

    ALTA CALIFORNIA MANAGEMENT PARTNERS II, LLC -- NEW POOL

    GRUENER GARRETT

    NOHRA GUY P

    JANNEY DANIEL

    • 10% Owner
    2,229,706 2006-10-03 0

    ALTA PARTNERS III, INC.

    MARDUEL ALIX

    ALTA BIOPHARMA MANAGEMENT III LLC

    ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG

    ALTA BIOPHARMA PARTNERS III LP

    ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC

    CHAMPSI FARAH

    HURWITZ EDWARD

    PENHOET EDWARD

    • 10% Owner
    2,229,706 2006-10-03 0

    DELEAGE JEAN

    • Director
    • 10% Owner
    2,642,583 2006-10-03 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 22:15:04 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 21:45:04 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 21:15:04 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 20:45:04 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 20:15:04 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 19:45:04 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 19:15:05 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 18:45:04 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 18:15:05 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 17:45:04 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 17:15:03 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 16:45:04 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 16:15:03 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 15:45:03 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 15:15:04 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 14:45:04 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 14:15:03 UTC -0.8111 3.1311 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 13:45:03 UTC -3.786 6.106 100000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 13:15:04 UTC -3.786 6.106 150000
    TURNING POINT THERAPEUTICS I TPTX 2022-08-17 12:45:04 UTC -3.786 6.106 150000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Index Plus All-Cap Fund TPTX -1.0 shares, $-44.66 2020-03-31 N-PORT
    Trust for Professional Managers- Convergence Long/Short Equity Fund TPTX -372.0 shares, $-14158.32 2021-11-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments